Shots:
- HistoSonics has reported CE Mark approval of its Edison System for the non-invasive mechanical destruction of liver tumors, incl. the partial or complete destruction of unresectable liver tumors using histotripsy
- Approval was supported by clinical evidence, incl. HOPE4LIVER trial, which demonstrated a 90% local tumor control rate at 12mos. across liver tumor types with a low complication rate. Long-term follow-up is ongoing to validate outcomes in real-world settings
- The Edison System is a non-invasive, image-guided histotripsy platform that uses focused ultrasound to liquefy & destroy tumors without surgery or radiation. HistoSonics plans a phased EU rollout, starting with select liver tumor treatment centers
Ref: Businesswire | Image: Histonics | Press Release
R
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
